Insmed (NASDAQ:INSM) Hits New 12-Month High - Time to Buy?

Key Points

• Insmed, Inc. (NASDAQ:INSM) reached a new 52-week high of $169.99, showing positive momentum in the market with a trading volume of 1383 shares.
• Analysts are optimistic, with numerous upgrades to target prices; Guggenheim set a new target of $172, and a consensus rating of "Moderate Buy" with an average target price of **$152.88**.
• Despite a revenue increase of 18.9% year-over-year, Insmed reported a disappointing EPS of -$1.70, missing expectations by $0.40.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $169.99 and last traded at $165.77, with a volume of 1383 shares changing hands. The stock had previously closed at $165.76.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Guggenheim increased their target price on Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research report on Monday, September 8th. Jefferies Financial Group increased their target price on Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. JPMorgan Chase & Co. increased their target price on Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a research report on Wednesday, August 20th. Stifel Nicolaus increased their target price on Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Finally, TD Cowen increased their target price on Insmed from $154.00 to $193.00 and gave the company a "buy" rating in a research report on Thursday, October 2nd. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $152.88.

Insmed Price Performance

The company has a market cap of $35.33 billion, a PE ratio of -29.27 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The stock has a 50 day moving average of $143.38 and a 200-day moving average of $105.27.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's revenue was up 18.9% on a year-over-year basis. During the same quarter last year, the business earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Equities analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the transaction, the chief executive officer directly owned 233,924 shares of the company's stock, valued at $30,035,841.60. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Roger Adsett sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the sale, the chief operating officer directly owned 105,637 shares in the company, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 152,657 shares of company stock worth $21,442,198. 3.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Insmed

Several large investors have recently bought and sold shares of the stock. Ethic Inc. acquired a new position in Insmed in the third quarter valued at $214,000. Everpar Advisors LLC acquired a new position in Insmed in the third quarter valued at $209,000. Apollon Wealth Management LLC acquired a new position in Insmed in the third quarter valued at $295,000. CWM LLC boosted its stake in Insmed by 41.8% in the third quarter. CWM LLC now owns 2,455 shares of the biopharmaceutical company's stock valued at $354,000 after acquiring an additional 724 shares in the last quarter. Finally, Yousif Capital Management LLC boosted its stake in shares of Insmed by 9.3% during the third quarter. Yousif Capital Management LLC now owns 2,188 shares of the biopharmaceutical company's stock worth $315,000 after buying an additional 187 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.